Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that preclinical data demonstrating that AT13387, a novel non-ansamycin Heat Shock Protein 90 (HSP90) inhibitor, is active in in vitro gastrointestinal stromal tumor (GIST) models (Abstract #9407) was presented at the 2011 ECCO (European Cancer Organization) European Multidisciplinary Cancer Congress in Stockholm, Sweden.


Astex Pharmaceuticals is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer.

Read the full article and the disclaimer at: http://drstockpick.com/?p=22242